Your fact-checks will appear here
Company in Gaithersburg, Maryland
Recent reporting and public-health documents show no consistent evidence that the updated 2024–25 or 2025–26 COVID-19 vaccines introduced wholly new, common side effects; surveillance and news coverag...
Pfizer and Moderna mRNA vaccines produce (injection-site pain, fatigue, headache, fever) that are generally mild and resolve in days, with likely due to a higher mRNA dose . Rare serious events differ...
Clinical-trial and post‑authorization reports for the 2024–2025 updated COVID vaccines show predictable, mostly short‑lived reactions — injection‑site pain/tenderness, fatigue, muscle aches, fever, he...
Adjuvants commonly used in licensed vaccines include aluminum salts (alum), oil‑in‑water emulsions such as MF59, saponin‑based complexes like QS21/Matrix‑M, toll‑like receptor (TLR) agonists such as m...
Available reporting shows both 2024–25/2025 updated mRNA boosters (Pfizer, Moderna) and a protein‑subunit booster (Novavax/Nuvaxovid) were offered and monitored for safety; several studies and news an...
Updated COVID-19 vaccines introduced for 2024–2025 and adjusted again for 2025 target recent Omicron descendants (JN.1, KP.2, LP.8.1 and related lineages) and provide clear protection against severe o...
Updated COVID-19 vaccine formulations in 2024–2026 focused on changing antigens to match circulating variants and expanding product lines (mRNA, protein/adjuvanted Novavax), but available reporting an...
Updated 2025–2026 COVID-19 boosters most commonly cause short-lived, mild-to-moderate reactions such as injection‑site pain, fatigue, fever, chills and headache; these are described in multiple patien...
Major COVID-19 vaccine platforms differ on preservatives, adjuvants and use of fetal‑derived cell lines: mRNA vaccines (Pfizer–BioNTech, Moderna) do not use traditional vaccine adjuvants and were not ...
Vaccine manufacturers Pfizer-BioNTech, Moderna and Novavax produced updated COVID-19 vaccine formulas for the 2023–2025 seasons; regulators authorized successive strain-updated monovalent versions (XB...
Clinical trial-era data and early post-rollout monitoring showed both Pfizer-BioNTech (Comirnaty) and Moderna (Spikevax) mRNA vaccines cause similar patterns of local and systemic side effects that ar...
Clinical reporting and guidance show that common immediate side effects are similar across Pfizer and Moderna (mRNA), Johnson & Johnson (adenoviral vector), and Novavax (protein subunit): injection‑si...
Regulatory guidance for the Janssen (Johnson & Johnson) COVID‑19 vaccine has shifted from broad emergency use in 2021 to a narrowly circumscribed role by 2024–2025: the FDA limited Janssen’s primary u...
mRNA boosters commonly produce transient local and systemic reactions — injection-site pain, fatigue, headache, muscle aches — and have been linked to rare myocarditis/pericarditis cases (for example ...
Modern U.S. COVID-19 vaccines are complex products whose full ingredient lists are provided in official package inserts and CDC product information; the CDC’s interim clinical considerations explicitl...
Available reporting and studies from 2024–2025 show that most 2025 booster formulations (mRNA and protein‑subunit types) produce short‑lived local and systemic side effects — typically soreness, fatig...
Updated 2024–2025 COVID vaccines produce the same common, short-lived reactions—sore arm, fatigue, headache, muscle pain, fever—as earlier mRNA boosters, and serious adverse events remain rare; large ...
mRNA boosters (Pfizer/Moderna) deliver the strongest and fastest antibody and T‑cell boosts and have shown greater durability of anti‑spike IgG after boosting than a two‑dose primary series, but neutr...
You asked for the full ingredient lists for Moderna and Janssen COVID‑19 vaccines and how they differ from Pfizer’s; available reporting in the provided sources discusses vaccine brands, approvals, an...
From 2023 to the 2024–2025 season, COVID‑19 vaccine compositions moved from formulations centered on the to updated vaccines targeting the , with both mRNA and protein‑based adjuvanted products adapte...